Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS

NCT04152018 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04152018
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04152018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
November 13, 2019
Completion date
December 10, 2024
Enrollment
85 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

bile duct cancer, endometrial cancer, esophageal cancer, gastric cancer, lung squamous cell carcinoma, melanoma cancer, ovarian cancer, pancreatic cancer, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial cancer